**Subject:** Please Protect Research Funding and Care Access for Amyloidosis Patients

Dear [Senator/Representative] [Last Name],

My name is [Your Name], and I am writing as a [patient/caregiver/family member/advocate] in the amyloidosis community. I’m reaching out because I’m deeply concerned about the recent federal policy changes that threaten the future of biomedical research and access to care in the U.S. As you consider fiscal year (FY) 2026 budget decisions, I urge you to protect biomedical research and public health by providing robust, sustained, and predictable funding for the NIH and continued support for Medicaid —two pillars of progress and access for those affected by rare and life-threatening diseases like amyloidosis.

Amyloidosis includes a group of complex, often fatal rare diseases caused by the accumulation of misfolded proteins in organs and tissues. These conditions are difficult to diagnose, require long-term management, and have limited treatment options. Thanks to federal investment, especially through the NIH, we are finally seeing meaningful advances in diagnosis, therapy development, and clinical trials.

Proposed cuts and restructuring at key agencies including NIH, FDA, and Medicaid have begun to disrupt the momentum of scientific discovery and patient care. Clinical trials are slowing. Early-career researchers are losing funding. Critical programs have been eliminated. Now, with FY 2026 budget decisions on the horizon, the situation has become more urgent than ever.

These changes threaten to:

* Delay research that could lead to earlier diagnosis and more effective treatments
* Reduce access to specialized care, which many amyloidosis patients receive through Medicaid and related programs
* Undermine FDA’s and NIH’s capacity to evaluate and support safe, innovative therapies.

As we face this pivotal moment, we ask that Congress not only protect, but actively reinvest in and strengthen the federal research and health infrastructure. Specifically, we urge you to:

* Support a base NIH funding level of at least $51.303 billion in FY 2026, enabling continued progress across research disciplines, including rare diseases;
* Preserve and expand Medicaid, which provides critical coverage for patients facing the high cost and complexity of managing amyloidosis;
* Ensure that agency leadership across NIH, FDA, and CMS uphold patient-centered policies and safeguard scientific momentum; and
* Work with the Administration to ensure all appropriated funds are spent as directed by Congress, and not withheld or redirected through executive action.

Thank you for your leadership and for standing with those affected by rare diseases. Your support helps ensure that innovation continues and no one with amyloidosis is left waiting for care, hope, or answers.

With appreciation,  
[Your Name]  
[Your Title / Affiliation]  
[Contact Information]